Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)
Denali Therapeutics (DNLI) posted quarterly Non Operating Income of $13.1 million for Q4 2023, up 97.13% year-over-year from $6.7 million in Q4 2022, and down 9.09% quarter-over-quarter from $14.4 million in Q3 2023.
Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has reported Non Operating Income for 7 consecutive years, with $13.1 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non Operating Income rose 97.13% year-over-year to $13.1 million; the TTM figure through Dec 2023 stood at $51.5 million (up 248.62% YoY), while the FY2023 annual figure was $51.5 million, up 248.62% from the prior year.
- Non Operating Income eased to $13.1 million in Q4 2023 per DNLI's latest filing, from $14.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $14.4 million in Q3 2023 and bottomed at $1.0 million in Q3 2021.
- Historically, Non Operating Income has averaged $5.2 million across 5 years, with a median of $3.1 million in 2020.
- Annual changes were most pronounced in 2020 — Non Operating Income sank 82.96% — and 2023, when it jumped 763.38%.
- Denali Therapeutics' Non Operating Income stood at $11.4 million in 2019, then plunged by 85.72% to $1.6 million in 2020, then retreated by 21.17% to $1.3 million in 2021, then jumped by 418.29% to $6.7 million in 2022, then jumped by 97.13% to $13.1 million in 2023.
- Business Quant data shows DNLI's Non Operating Income at $13.1 million in Q4 2023, $14.4 million in Q3 2023, and $12.9 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13.13 Mn |
| Sep 30, 2023 | 14.44 Mn |
| Jun 30, 2023 | 12.90 Mn |
| Mar 31, 2023 | 11.03 Mn |
| Dec 31, 2022 | 6.66 Mn |
| Sep 30, 2022 | 4.19 Mn |
| Jun 30, 2022 | 2.65 Mn |
| Mar 31, 2022 | 1.28 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 1.13 Mn |
| Mar 31, 2021 | 1.18 Mn |
| Dec 31, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.94 Mn |
| Jun 30, 2020 | 2.60 Mn |
| Mar 31, 2020 | 3.07 Mn |
| Sep 30, 2019 | 11.41 Mn |
| Jun 30, 2019 | 4.11 Mn |
| Mar 31, 2019 | 3.52 Mn |
| Dec 31, 2018 | 2.81 Mn |